Multimarker risk assessment including osteoprotegerin and CXCL16 in acute coronary syndromes

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 12, 2012, Pages 3041-3049

  Jansson, Anna M ^a   Hartford, Marianne ^b   Omland, Torbjørn ^d,e   Karlsson, Thomas ^b   Lindmarker, Per ^a   Herlitz, Johan ^b,c   Ueland, Thor ^e   Aukrust, Pål ^e,f   Caidahl, Kenneth ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF BORÅS   (Sweden)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

Author keywords

acute myocardial infarction; atherosclerosis; biomarkers; inflammation; prognostic factors

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CXCL16 CHEMOKINE; OSTEOPROTEGERIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART REINFARCTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; CHEMOKINES, CXC; FEMALE; HEART FAILURE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, SCAVENGER; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE;

EID: 84870056913     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300326     Document Type: Article

References (37)

1. GonzalezQuesada C, Frangogiannis NG. Monocyte chemoattractant protein1/CCL2 as a biomarker in acute coronary syndromes. Curr Atheroscler Rep. 2009;11:131-138.
2. Roubille F, Samri A, Cornillet L, SportouchDukhan C, Davy JM, Raczka F, Gervasoni R, Pasquie JL, Cung TT, Piot C, Macia JC, Cransac F, Leclercq F. Routinelyfeasible multiple biomarkers score to predict prognosis after revascularized STEMI. Eur J Intern Med. 2010;21:131-136.
3. Aragam KG, Tamhane UU, KlineRogers E, Li J, Fox KA, Goodman SG, Eagle KA, Gurm HS. Does simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of the TIMI and GRACE risk scores. PLoS ONE. 2009;4:e7947.
4. Yan AT, Yan RT, Tan M, Casanova A, Labinaz M, Sridhar K, Fitchett DH, Langer A, Goodman SG. Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J. 2007;28:1072-1078. (Pubitemid 47343862)
5. Pietilä KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serum Creactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of followup in patients under thrombolytic treatment. Eur Heart J. 1996;17:1345-1349. (Pubitemid 26306662)
6. Zairis MN, Adamopoulou EN, Manousakis SJ, Lyras AG, Bibis GP, Ampartzidou OS, Apostolatos CS, Anastassiadis FA, Hatzisavvas JJ, Argyrakis SK, Foussas SG; Biomarkers of Inflammation and Outcome in Acute Coronary Syndromes (BIAS) Investigators. The impact of hs Creactive protein and other inflammatory biomarkers on longterm cardiovascular mortality in patients with acute coronary syndromes. Atherosclerosis. 2007;194:397-402. (Pubitemid 47513066)
7. Jansson AM, Aukrust P, Ueland T, Smith C, Omland T, Hartford M, Caidahl K. Soluble CXCL16 predicts longterm mortality in acute coronary syndromes. Circulation. 2009;119:3181-3188.
8. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, Caidahl K. Circulating osteoprotegerin levels and longterm prognosis in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;51:627-633. (Pubitemid 351193104)
9. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK, de Lemos JA. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol. 2007;99:513-518. (Pubitemid 46215559)
10. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006;47:1850-1857.
11. Smith C, Halvorsen B, Otterdal K, Waehre T, Yndestad A, Fevang B, Sandberg WJ, Breland UM, Frøland SS, Oie E, Gullestad L, Damås JK, Aukrust P. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: downregulatory effects of statins. Cardiovasc Res. 2008;79:195-203. (Pubitemid 351881937)
12. Sandberg WJ, Yndestad A, Øie E, et al. Enhanced Tcell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol. 2006;26:857-863. (Pubitemid 43732163)
13. Mangan SH, Van Campenhout A, Rush C, Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factoralpha associated with induction of angiopoietin2. Cardiovasc Res. 2007;76:494-505. (Pubitemid 350007458)
14. Barlic J, Zhu W, Murphy PM. Atherogenic lipids induce highdensity lipoprotein uptake and cholesterol efflux in human macrophages by upregulating transmembrane chemokine CXCL16 without engaging CXCL16dependent cell adhesion. J Immunol. 2009;182:7928-7936.
15. Wuttge DM, Zhou X, Sheikine Y, Wågsäter D, Stemme V, Hedin U, Stemme S, Hansson GK, Sirsjö A. CXCL16/SRPSOX is an interferongammaregulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2004;24:750-755. (Pubitemid 38451615)
16. Shimaoka T, Nakayama T, Fukumoto N, Kume N, Takahashi S, Yamaguchi J, Minami M, Hayashida K, Kita T, Ohsumi J, Yoshie O, Yonehara S. Cell surfaceanchored SRPSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6expressing cells. J Leukoc Biol. 2004;75:267-274. (Pubitemid 38174584)
17. Dahl CP, Husberg C, Gullestad L, Waehre A, Damås JK, Vinge LE, Finsen AV, Ueland T, Florholmen G, Aakhus S, Halvorsen B, Aukrust P, Oie E, Yndestad A, Christensen G. Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling. Circ Heart Fail. 2009;2:624-632.
18. Liu W, Feng W, Wang F, Li W, Gao C, Zhou B, Ma M. Osteoprotegerin/RANK/ RANKL axis in cardiac remodeling due to immunoinflammatory myocardial disease. Exp Mol Pathol. 2008;84:213-217.
19. Perers E, Caidahl K, Herlitz J, Sjölin M, Karlson BW, Karlsson T, Hartford M. Spectrum of acute coronary syndromes: history and clinical presentation in relation to sex and age. Cardiology. 2004;102:67-76. (Pubitemid 39077799)
20. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, Hartford M, Caidahl K. Nterminal proBtype natriuretic peptide and longterm mortality in acute coronary syndromes. Circulation. 2002;106:2913-2918. (Pubitemid 35424741)
21. Caidahl K, Kazzam E, Lidberg J, Neumann Andersen G, Nordanstig J, Rantapää Dahlqvist S, Waldenström A, Wikh R. New concept in echocardiography: harmonic imaging of tissue without use of contrast agent. Lancet. 1998;352:1264-1270. (Pubitemid 28470339)
22. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg PG, Gore JM, Budaj A, Avezum A, Flather MD, Fox KA; GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6month postdischarge death in an international registry. JAMA. 2004;291:2727-2733. (Pubitemid 38725422)
23. DeLong ER, DeLong DM, ClarkePearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
24. de Paz JL, Moseman EA, Noti C, Polito L, von Andrian UH, Seeberger PH. Profiling heparinchemokine interactions using synthetic tools. ACS Chem Biol. 2007;2:735-744. (Pubitemid 350285909)
25. Abel S, Hundhausen C, Mentlein R, Schulte A, Berkhout TA, Broadway N, Hartmann D, Sedlacek R, Dietrich S, Muetze B, Schuster B, Kallen KJ, Saftig P, RoseJohn S, Ludwig A. The transmembrane CXCchemokine ligand 16 is induced by IFNgamma and TNFalpha and shed by the activity of the disintegrinlike metalloproteinase ADAM10. J Immunol. 2004;172:6362-6372. (Pubitemid 38621245)
26. Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005;111:2461-2468. (Pubitemid 40696134)
27. Helske S, Kovanen PT, Lindstedt KA, Salmela K, Lommi J, Turto H, Werkkala K, Kupari M. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail. 2007;9:357-363. (Pubitemid 46441975)
28. Noheria A, Mosley TH Jr., Kullo IJ. Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension. Am J Hypertens. 2010;23:767-774.
29. Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, de Lemos JA. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension. 2007;49:1392-1398. (Pubitemid 46809385)
30. Candido R, Toffoli B, Corallini F, Bernardi S, Zella D, Voltan R, Grill V, Celeghini C, Fabris B. Human fulllength osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J Vasc Res. 2010;47:252-261.
31. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, Squire IB, Gullestad L, Bollerslev J, Dickstein K, Aukrust P. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol. 2004;44:1970-1976. (Pubitemid 39473280)
32. Zhang L, Ran L, Garcia GE, Wang XH, Han S, Du J, Mitch WE. Chemokine CXCL16 regulates neutrophil and macrophage infiltration into injured muscle, promoting muscle regeneration. Am J Pathol. 2009;175:2518-2527.
33. Lehrke M, Millington SC, Lefterova M, Cumaranatunge RG, Szapary P, Wilensky R, Rader DJ, Lazar MA, Reilly MP. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol. 2007;49:442-449. (Pubitemid 46135882)
34. Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004;35:1636-1641. (Pubitemid 38823639)
35. Caidahl K, Ueland T, Aukrust P. Osteoprotegerin: a biomarker with many faces. Arterioscler Thromb Vasc Biol. 2010;30:1684-1686.
36. Ang DS, Wei L, Kao MP, Lang CC, Struthers AD. A comparison between Btype natriuretic peptide, global registry of acute coronary events (GRACE) score and their combination in ACS risk stratification. Heart. 2009;95:1836-1842.
37. Schiele F, Meneveau N, Seronde MF, Chopard R, DescotesGenon V, Dutheil J, Bassand JP; Reseau de Cardiologie de Franche Comte. Creactive protein improves risk prediction in patients with acute coronary syndromes. Eur Heart J. 2010;31:290-297.